Skip to content
OpenCapital
Get started

abrdn Income Credit Strategies ACP Pharma — Number Of Approved Therapies

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$0+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by abrdn Income Credit Strategies in its filing.

Tagged under the XBRL concept iep:NumberOfApprovedTherapies.

The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about abrdn Income Credit Strategies's pharma — number of approved therapies.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is abrdn Income Credit Strategies's pharma — number of approved therapies?
abrdn Income Credit Strategies (ACP) reported pharma — number of approved therapies of 2 in Q1 2026.
How has abrdn Income Credit Strategies's pharma — number of approved therapies changed year-over-year?
abrdn Income Credit Strategies's pharma — number of approved therapies decreased by 0.0% year-over-year, from 2 to 2.
What does pharma — number of approved therapies mean?
The total count of pharmaceutical products or therapies that have received regulatory approval for commercial sale and distribution. This metric serves as a key indicator of the segment's commercial maturity and its ability to successfully navigate the regulatory approval process.